of new a-amylase assay using 4,6-ethylidene-(G7)-1-4-nitrophenyl-(G1)-a-D-maltoheptaoside as substrate.
zymes
. Unfortunately, the method was not applicable to a double kinetic assay (DKA). Therefore, we have been studying an inhibitor method and recently reported that deoxymaltooligosaccharides with a 6-deoxy-D-glucosyl group at the nonreducing end were potent selective HPA inhibitors (15) .
Among them, 63-deoxymaltotriose (DOG3; see Fig. 1 ) showed the greatest difference in inhibitory activity between HPA and HSA, and could be applied to the differential assay of a-amylases by using standard enzymes.
In this report we describe an automated measurement of a-amylase isoenzymes in serum by single kinetic assay (SKA) and DKA with 2-chloro-4-nitrophenyl and with DOG3 on a Hitachi 917 automated analyzer.
We developed an automated method for measurement of a-amylase isoenzymes in serum by a single kinetic assay (SKA) and a double kinetic assay (DKA) with 2-chloro-4-nitrophenyl-65-azido-65-deoxy-f3-maltopentaoside as a substrate and 63-deoxymaltotriose (DOG3) as a novel selective amylase inhibitor. DOG3 showed a large difference in inhibitory activity between human pancreatic a-amylase (HPA; 86.9% inhibition) and salivary a-amylase (32.1 % inhibition) at 0.33 mmoVL Constant inhibition was obtained immediately after addition of DOG3. 
Instruments.
We used a Hitachi 917 automated analyzer (Hitachi, Tokyo, Japan) for our differential I1PA, human pancreatic a-amylase; HSA, human salivary a-amylase; mAli, monoclonal antibody; and CNP, 2-chloro-4-nitrophenol.
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Materials and Methods

Principle of the Reaction
Instrumentation and Reagents with a mAb or a WGI method. Settings for the WGI method were as follows: sample volume 4 p1, R-la or R-lb 200 pl. R-3a 100 p1, wavelength 660/405 nm, and temperature 37#{176}C. After mixing the sample and R-la or R-lb for 5 mm, the reaction was started by adding R-3a; after 2 mm the absorbance at 660/405 nm was monitored for 3 mm. Calculation. Fig. 3 shows that the maximum difference in inhibitory activity between the two a-amylases is achieved at 0.33 mmol/L DOG3, and the remaining activities of EPA and HSA are 13.1% and 67.9%, respectively.
When a sample containing EPA and HSA hydrolyzes the substrate with or without inhibitor DOG3, the equations for the differential assay are as follows:
the SKA and the mAb, WGI, or DKA methods 0.988, 0.989, and 0.995 That is, the Discussion degrees of inhibitory activity for EPA and HSA were We have recently developed a method for measureconstant over the range of enzyme concentrations ment of total a-amylase activity in serum by using tested.
N3G5CNP ( In conclusion, the present differential assay method is simple and precise, and can be automated and run in a brief time, with good correlation and good cost performance with DKA using N3G5CNP and DOG3. We anticipate that this proposed assay method will become widely used for accurate diagnosis of various diseases.
